These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 23503607)

  • 1. Autoimmunity and persistent RAS-mutated clones long after the spontaneous regression of JMML.
    Takagi M; Piao J; Lin L; Kawaguchi H; Imai C; Ogawa A; Watanabe A; Akiyama K; Kobayashi C; Mori M; Ko K; Sugimoto M; Mizutani S
    Leukemia; 2013 Sep; 27(9):1926-8. PubMed ID: 23503607
    [No Abstract]   [Full Text] [Related]  

  • 2. [Molecular mechanism and treatment of juvenile myelomonocytic leukemia (JMML)].
    Manabe A
    Rinsho Ketsueki; 2012 Aug; 53(8):729-33. PubMed ID: 22975811
    [No Abstract]   [Full Text] [Related]  

  • 3. Control of thrombotic thrombocytopenic purpura by sirolimus in a child with juvenile myelomonocytic leukemia and somatic N-RAS mutation.
    Maschan M; Bobrynina V; Khachatryan L; Kalinina I; Solopova G; Avdonin P; Nasedkina T; Novichkova G; Maschan A
    Pediatr Blood Cancer; 2014 Oct; 61(10):1871-3. PubMed ID: 24590757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular biology of juvenile myelomonocytic leukemia (JMML)].
    Manabe A
    Rinsho Ketsueki; 2010 Jul; 51(7):526-31. PubMed ID: 20693772
    [No Abstract]   [Full Text] [Related]  

  • 5. Spontaneous remission of juvenile myelomonocytic leukemia with NRAS mutation.
    Alsultan A; Khalifah M; Alrabiaah AA
    Pediatr Hematol Oncol; 2012 Oct; 29(7):624-6. PubMed ID: 22857389
    [No Abstract]   [Full Text] [Related]  

  • 6. The strange case of the lost NRAS mutation in a child with juvenile myelomonocytic leukemia.
    De Filippi P; Zecca M; Novara F; Lisini D; Maserati E; Pasquali F; Rosti V; Carlo-Stella C; Zavras N; Cagioni C; Zuffardi O; Pagliara D; Danesino C; Locatelli F
    Pediatr Blood Cancer; 2012 Sep; 59(3):580-2. PubMed ID: 22183880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
    Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
    Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular mechanism and progress in treatment of juvenile myelomonocytic leukemia (JMML)].
    Koike K; Matsuda K
    Rinsho Ketsueki; 2013 Jun; 54(6):538-44. PubMed ID: 23823092
    [No Abstract]   [Full Text] [Related]  

  • 9. [Gene mutations and clinical characteristics in children with juvenile myelomonocytic leukemia].
    Yang WY; Chen XJ; Wang SC; Guo Y; Liu TF; Chang LX; Liu F; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jan; 17(1):1-5. PubMed ID: 25616283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of granulocyte-macrophage colony-stimulating factor hypersensitivity in juvenile myelomonocytic leukemia by 3H-thymidine assay.
    Tanaka M; Takahashi Y; Xu Y; Yoshida N; Yoshimi A; Villalobos IB; Hama A; Nishio N; Hidaka H; Wang Y; Yagasaki H; Kojima S
    Leuk Res; 2008 Jul; 32(7):1036-42. PubMed ID: 18164384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAS pathway mutations in juvenile myelomonocytic leukemia.
    Emanuel PD
    Acta Haematol; 2008; 119(4):207-11. PubMed ID: 18566538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation analysis of the BRAF oncogene in juvenile myelomonocytic leukemia.
    de Vries AC; Stam RW; Kratz CP; Zenker M; Niemeyer CM; van den Heuvel-Eibrink MM;
    Haematologica; 2007 Nov; 92(11):1574-5. PubMed ID: 18024410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia.
    De Filippi P; Zecca M; Lisini D; Rosti V; Cagioni C; Carlo-Stella C; Radi O; Veggiotti P; Mastronuzzi A; Acquaviva A; D'Ambrosio A; Locatelli F; Danesino C
    Br J Haematol; 2009 Dec; 147(5):706-9. PubMed ID: 19775298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities.
    Calvo KR; Price S; Braylan RC; Oliveira JB; Lenardo M; Fleisher TA; Rao VK
    Blood; 2015 Apr; 125(18):2753-8. PubMed ID: 25691160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.
    Stieglitz E; Mazor T; Olshen AB; Geng H; Gelston LC; Akutagawa J; Lipka DB; Plass C; Flotho C; Chehab FF; Braun BS; Costello JF; Loh ML
    Nat Commun; 2017 Dec; 8(1):2127. PubMed ID: 29259179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemophagocytosis associated with leukemia: a striking association with juvenile myelomonocytic leukemia.
    Unal S; Cetin M; Kutlay NY; Elmas SA; Gumruk F; Tukun A; Tuncer M; Gurgey A
    Ann Hematol; 2010 Apr; 89(4):359-64. PubMed ID: 19798502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group.
    Bresolin S; De Filippi P; Vendemini F; D'Alia M; Zecca M; Meyer LH; Danesino C; Locatelli F; Masetti R; Basso G; Te Kronnie G
    Oncotarget; 2016 May; 7(20):28914-9. PubMed ID: 26980750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic mosaicism for a NRAS mutation associates with disparate clinical features in RAS-associated leukoproliferative disease: a report of two cases.
    Shiota M; Yang X; Kubokawa M; Morishima T; Tanaka K; Mikami M; Yoshida K; Kikuchi M; Izawa K; Nishikomori R; Okuno Y; Wang X; Sakaguchi H; Muramatsu H; Kojima S; Miyano S; Ogawa S; Takagi M; Hata D; Kanegane H
    J Clin Immunol; 2015 Jul; 35(5):454-8. PubMed ID: 25896945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative assessment of PTPN11 or RAS mutations at the neonatal period and during the clinical course in patients with juvenile myelomonocytic leukaemia.
    Matsuda K; Sakashita K; Taira C; Tanaka-Yanagisawa M; Yanagisawa R; Shiohara M; Kanegane H; Hasegawa D; Kawasaki K; Endo M; Yajima S; Sasaki S; Kato K; Koike K; Kikuchi A; Ogawa A; Watanabe A; Sotomatsu M; Nonoyama S; Koike K
    Br J Haematol; 2010 Feb; 148(4):593-9. PubMed ID: 19874312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations.
    Sugimoto Y; Muramatsu H; Makishima H; Prince C; Jankowska AM; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP
    Br J Haematol; 2010 Jul; 150(1):83-7. PubMed ID: 20408841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.